This website is intended for US healthcare professionals only. Prescribing Information Important Safety Information

Template Desktop

How to reconstitute CEPROTIN

CEPROTIN is administered by intravenous injection after reconstitution of the lyophilized powder for solution with sterilized water for injections1

Initiate treatment with CEPROTIN under the supervision of a physician experienced in replacement therapy with coagulation factors/inhibitors where monitoring of protein C activity is feasible.1

How to reconstitute CEPROTIN: Use aseptic technique


Bring the CEPROTIN (powder) and Sterile Water for Injection, USP (diluent) to room temperature.


Remove caps from the CEPROTIN and diluent vials.


Cleanse stoppers with germicidal solution, and allow them to dry prior to use.


Remove protective covering from one end of the double-ended transfer needle and insert exposed needle through the center of the diluent vial stopper.


Remove protective covering from the other end of the double-ended transfer needle. Invert diluent vial over the upright CEPROTIN vial; then rapidly insert the free end of the needle through the CEPROTIN vial stopper at its center. The vacuum in the vial will draw in the diluent. If there is no vacuum in the vial, do not use the product.


Disconnect the two vials by removing the needle from the diluent vial stopper. Then, remove the transfer needle from the CEPROTIN vial. Gently swirl the vial until all powder is dissolved. Be sure that CEPROTIN is completely dissolved; otherwise, active materials will be removed by the filter needle.

Please refer to the full prescribing information for complete information on Dosage and Administration.1

How to dose CEPROTINCEPROTIN manufacturing

Click arrow for Indication and Important Safety Information

Warnings and Precautions

Hypersensivity: CEPROTIN may contain trace amounts of mouse protein and/or heparin as a result of the manufacturing process. Allergic reactions to mouse protein and/or heparin cannot be ruled out. If symptoms of hypersensitivity/allergic reaction occur, discontinue the injection/infusion. In case of anaphylactic shock, the current medical standards for treatment are to be observed.


  1. CEPROTIN [Protein C Concentrate (Human)] Prescribing information. Lexington, MA: Baxalta US Inc.

Sign up below

The contact information collected in this form will be used for subscribing to our newsletter and updates on educational activities.

Sorry! There are some errors below that need to be fixed.

You have the right to opt out of receiving such electronic communications and/or our newsletter, at any time, by using the opt out link in the communication or by contacting us at or by calling 1-866-888-0660. For more information on how Takeda processes your personal data, please refer to our Privacy Notice

Please include @ in your email address (eg


Thank you for submitting your details.

You are about to leave this website
Please be advised that Takeda has no control over the content or presentation of the site your are to view. Takeda's Privacy Notice does not apply to the website you are about to visit.
Continue Cancel